idea-011 · human · queued-research
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
This candidate has no ## Wrap section yet, so there is no plain-language summary, no quoted load-bearing condition per lens, and no named cheapest next test. Run /wrap idea-011 to write one.
| Intended use | For continuous ambulatory ECG-based screening, as an adjunct to and not a; replacement for laboratory potassium measurement, to flag possible hyperkalemia between; scheduled visits in adult outpatients with chronic kidney disease or heart failure; undergoing initiation or up-titration of a renin-angiotensin-aldosterone system inhibitor,; with any flagged reading requiring confirmatory testing before a clinical decision is made. |
|---|---|
| Mechanism | Adhesive-patch single- or multi-lead ECG sensor worn continuously between clinic; visits, streaming waveform data to a paired reader; an onboard or cloud deep-learning model; scores ECG morphology (e.g. T-wave changes historically associated with hyperkalemia) for; hyperkalemia risk and pushes an alert to the prescribing clinic, prompting a confirmatory; lab or point-of-care potassium draw rather than replacing one |
| Device class | # Two live routes, and neither is confirmed — the central open; Class II — regulation and product code NOT identified by the Generator — 510(k) route,; contingent on a cleared ECG-based hyperkalemia-screening predicate existing at time of; submission. The Generator could not confirm any such predicate is currently cleared (see; claims 1-2), so this route may not be live at all.; De Novo — regulation not yet created — the route that applies if no cleared predicate; exists for ECG-morphology-based hyperkalemia screening at time of submission. Carried as; at least as likely as the 510(k) route given claim 2. |
| Predicate or analog | AliveCor's KardiaK Software Platform — an ECG-based, deep-learning; hyperkalemia-screening algorithm that received FDA Breakthrough Device Designation in; September 2018 (see claim 1) — is the closest analog by mechanism, not a confirmed; predicate: the Generator's web search found no confirmation that KardiaK has since been; cleared or De Novo-granted (claim 2). No K-number or De Novo number identified. Adjacent; academic anchor: a Mayo Clinic-led deep-learning ECG hyperkalemia-screening model (PMID; 30942845), a research result, not a cleared product. |
| Launch jurisdiction | US |
| Target | human |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 2 | openFDA 510(k) database search for a cleared ECG-hyperkalemia-screening predicate (by product code); FDA De Novo database search for the same |
| Reimbursement pathway | 1 | Federal Register docket status check on document 2026-16368 (91 FR 51710) for finalization; CMS HCPCS/RPM code applicability determination via a data/ CMS file pull; LCD/NCD search for ECG-based hyperkalemia screening |
| TAM | 2 | Direct extraction of Medicare FFS CKD beneficiary counts from the USRDS 2024 Annual Data Report; CMS RPM payment rate as a price proxy; a licensed commercial-claims/market report for addressable share (human-attached per data/README.md) |
| FTO / IP | 2 | USPTO/Google Patents assignee search for AliveCor and adjacent ECG-hyperkalemia patent families, down to a specific patent number |
| Moat / defensibility | 2 | Patent landscape scan beyond bare FTO (claim scope, expiration dates) plus a count of other named entrants pursuing ECG-based hyperkalemia screening |
| Mechanism & clinical risk | 3 | Full-text primary-source read of PMID 30942845 (methodology, validation cohort, external validation) plus a search for any subsequent prospective/multi-site validation study |
| Capital intensity & time-to-revenue | 2 | Published FDA De Novo review-timeline statistics for comparable product codes; Federal Register docket tracking for 2026-16368's finalization timeline |
| Competitive intensity | 2 | FDA Breakthrough Device Designation public list plus a search for recent clearances/funding/launches in ECG-based hyperkalemia screening |
| Strategic fit & portfolio balance | — | Internal portfolio review (human judgment, Stage 6/7), not a connector lookup |
To finish this packet:
## Wrap section with a **Cheapest next test:** lineDomain dossier: potassium-monitoring-ckd
Source file: knowledge-base/candidates/idea-011.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.